Back Article

Burnside MJ, Lewis DM, Crocket HR, Meier RA, Williman JA, et al. 2022. Open-source automated insulin delivery in type 1 diabetes. New England Journal of Medicine 387(10):869−881

American Diabetes Association Professional Practice Committee. 2025. Diabetes technology: standards of care in diabetes—2025. Diabetes Care 48:S146–S166

Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, et al. 2022. Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the joint diabetes technology working group of the European association for the study of diabetes and the american diabetes association. Diabetes Care 45(12):3058−3074

Yang Q, Zeng B, Hao J, Yang Q, Sun F. 2024. Real-world glycaemic outcomes of automated insulin delivery in type 1 diabetes: a meta-analysis. Diabetes, Obesity and Metabolism 26(9):3753−3763

Messer LH, Forlenza GP, Gonder-Frederick L, Hood K, Ebekozien O, et al. 2025. Practical considerations and implementation of automated insulin delivery systems. Diabetes Technology & Therapeutics 27(S3):S72−S78

Lingen K, Maahs D, Bellini N, Isaacs D. 2024. Removing barriers, bridging the gap, and the changing role of the health care professional with automated insulin delivery systems. Diabetes Technology & Therapeutics 26(S3):45−52

Tanenbaum ML, Commissariat PV, Wilmot EG, Lange K. 2025. Navigating the unique challenges of automated insulin delivery systems to facilitate effective uptake, onboarding, and continued use. Journal of Diabetes Science and Technology 19(1):47−53

Lewis D, Leibrand S. 2016. Real-world use of open-source artificial pancreas systems. Journal of Diabetes Science and Technology 10(6):1411

Lee JM, Newman MW, Gebremariam A, Choi P, Lewis D, et al. 2017. Real-world use and self-reported health outcomes of a patient-designed do-it-yourself mobile technology system for diabetes: lessons for mobile health. Diabetes Technology & Therapeutics 19(4):209−219

OpenAPS. 2024. About the OpenAPS data commons on open humans. www.openhumans.org/activity/openaps-data-commons

Zhou Y, Lei M, Yang D, Ling P, Ni Y, et al. 2024. Real-world efficacy and safety of open-source automated insulin delivery for people with type 1 diabetes mellitus: experience from mainland China. Diabetes Research and Clinical Practice 218:111910

Liarakos AL, Crabtree TSJ, Hussain S, Patel R, Gazis A, et al. 2025. Long-term improvements in glycemia and user-reported outcomes associated with open-source automated insulin delivery systems in adults with type 1 diabetes in the United Kingdom: a real-world observational study. Diabetes Technology & Therapeutics 27:283−291

Braune K, Lal RA, Petruželková L, Scheiner G, Winterdijk P, et al. 2022. Open-source automated insulin delivery: international consensus statement and practical guidance for health-care professionals. The Lancet Diabetes & Endocrinology 10:58−74

Huhndt A, Chen Y, O'Donnell S, Cooper D, Ballhausen H, et al. 2022. Barriers to uptake of open-source automated insulin delivery systems: analysis of socioeconomic factors and perceived challenges of caregivers of children and adolescents with type 1 diabetes from the OPEN survey. Frontiers in Clinical Diabetes and Healthcare 3:876511

WHO Multicentre Growth Reference Study Group. 2006. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height, and body mass index-for-age: methods and development. Geneva: World Health Organization www.who.int/publications/i/item/924154693X

de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, et al. 2007. Development of a WHO growth reference for school-aged children and adolescents. Bulletin of the World Health Organization 85:660−667

Statistics Canada. 2019. The Canadian index of multiple deprivation—user guide. Stat Canada Cat No 45-20-0001. https://www150.statcan.gc.ca/n1/pub/45-20-0001/452000012019002-eng.htm

Wu Z, Lebbar M, Bonhoure A, Raffray M, Devaux M, et al. 2025. Open-source versus commercial automated insulin delivery system for type 1 diabetes management: a prospective observational comparative study from Canada. Diabetes Technology & Therapeutics 27:517−526

Landau Z, Lebenthal Y, Mazor-Aronovitch K, Brener A, Levek N, et al. 2024. A comparison of the usage of an open-source automated insulin delivery system and the MiniMed™ 780 G system in children and adolescents with type 1 diabetes in real-world settings: the AWeSoMe study group. Endocrine 84:943−950

Santova A, Plachy L, Neuman V, Pavlikova M, Petruzelkova L, et al. 2023. Are all HCL systems the same? Long-term outcomes of three HCL systems in children with type 1 diabetes: real-life registry-based study. Frontiers in Endocrinology 14:1283181

Lomax KE, Taplin CE, Abraham MB, Smith GJ, Haynes A, et al. 2024. Improved glycemic outcomes with diabetes technology use independent of socioeconomic status in youth with type 1 diabetes. Diabetes Care 47:707−711

Viner RM, White B, Amin R, Peters C, Khanolkar A, et al. 2017. Impact of deprivation, ethnicity, and insulin pump therapy on developmental trajectories of diabetes control in COB type 1 diabetes. Pediatric Diabetes 18:384−391

Soliman Y, Everett K, Shulman R, Austin PC, Lipscombe L, et al. 2025. Impact of social disadvantage on clinical and health care use indicators in adults with type 1 diabetes using insulin pumps in Ontario, Canada. Diabetes, Obesity & Metabolism 27:4998−5007

Gao G, Chen H, Sun H. 2024. Risk predictors of glycaemic control in children and adolescents with type 1 diabetes: a systematic review and meta-analysis. Journal of Clinical Nursing 33:2412−2426

Konantambigi A, Wang W, Boggild D, Rana A, Syphers L, et al. 2025. Real-world evaluation of automated insulin delivery therapy in type 1 diabetes: a multicentre study across regional and metropolitan Queensland, Australia. Diabetes, Obesity & Metabolism 27:4436−4445